P-0274 Liver Metastatic Colorectal Cancer (Mcrc) Bevacizumab Treated: CT Evaluation Using Software that Automatically Generates Report According to Recist Criteria

ABSTRACT Introduction The aim of this retrospective study is to define the usefulness of an integrated CT software that automatically generates report according to RECIST 1.1 criteria and Choi criteria, evaluating the effects of bevacizumab based chemotherapy on CRC liver metastases. Methods 35 patients with a total of 144 CRC liver metastases underwent CT before and after treatment and for each patient was recorded reporting time. Patients with peritoneal disease were excluded. CT images were reviewed by two radiologists in consensus, in order to correlate clinical values with CT images using software (Median, Technologies, France) that automatically synchronizes the images and pairs lesions in repeat CT scans according to RECIST 1.1 criteria as well as lesion density variation using Choi criteria. Results Reports showed a good correlation between CT images and laboratory values in 31out of 35 patients during the period of response and in 29 out of 35 during the period of disease progression. The associated use of Choi criteria, evaluating lesion density, provided a better correlation in 33 out of 35 patients during the period of clinical response to therapy and in 31out of 35 during the period of disease progression. In 6 patients with 21 lesions, lesion density difficulty matches with laboratory values due to either the presence of calcifications or the lesion of small size. Average reporting time ranged between 16 to 18 minutes. According to recent literature, serum level biomarkers correlated with both the history disease and the number of circulating tumor cells using CellSearch system, always results zero. Conclusion Using this software we provide accurate quantitative assessment of the response to bevacizumab based chemotherapy in liver mCRC showing a good correlation between imaging and laboratory values.